<DOC>
	<DOCNO>NCT02586246</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy CDP870 self-injection administer 24 week longer subject participate long-term treatment study ( Study 275-08-002 Study 275-08-004 ) CDP870 administer concomitantly without Methotrexate .</brief_summary>
	<brief_title>Long-term Treatment Study CDP870 Self-injection Patients With Active Rheumatoid Arthritis Who Are Participating Long-term Treatment Studies ( Study 275-08-002 Study 275-08-004 ) CDP870</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects complete treatment parent clinical study ( NCT00851318 NCT00850343 ) 52 week Subjects willing undertake selfinjection provide write consent Patients serious adverse event Patients judge investigator/subinvestigator ineligible participation study reason uncooperative attitude nonadherence study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Long-term</keyword>
</DOC>